Biopharma

Using n-3 DPA-derived Resolvins for Cardiovascular Diseases

 

A novel therapeutic strategy, using n-3 DPA-derived resolvins to treat or prevent cardiovascular disease.

Circadian rhythms play a key role in regulating various physiological functions, including cardiovascular health and the immune system. There is evidence linking disturbances in circadian responses to inflammatory conditions, including myocardial infarction.

Platelet activation is shown to be at its peak during the early morning hours, potentially increasing the risk of thrombosis. Recent studies have shown that n-3 DPA-derived resolvins are also regulated in a diurnal manner and are markedly altered in patients at risk of myocardial infarct.

Queen Mary researchers have developed a method for assessing a patient’s risk of cardiovascular disease, including myocardial infarction, related to an inadequate control of platelet and leukocyte activation. The method involves assessing the levels of multiple n-3 DPA-derived resolvins in biological samples, particularly in the early morning.

Using patient samples, it was demonstrated that n-3 DPA-derived resolvins reduce leukocyte and platelet activation. Furthermore, due to the negative correlation found between plasma and immune cell activation, n-3 DPA-derived resolvins can be used to assess the risk of cardiovascular diseases and the efficacy of therapeutic treatments.

A patent has been filed in the UK, USA, Europe and Japan. 

 

Contact

Dr Mark Gurden – m.gurden@qmul.ac.uk

 

Inventor

Professor Jesmond Dalli, Professor of Molecular Pharmacology